Lineage Cell Therapeutics
LCTX
94 hedge funds and large institutions have $48.5M invested in Lineage Cell Therapeutics in 2020 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 17 increasing their positions, 20 reducing their positions, and 23 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 23
3% less funds holding
Funds holding: 97 → 94 (-3)
5.45% less ownership
Funds ownership: 42.63% → 37.18% (-5.4%)
8% less capital invested
Capital invested by funds: $52.9M → $48.5M (-$4.41M)
15% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 20
Top Buyers
| 1 |
Jane Street
New York
|
+$710K |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$670K |
| 3 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$287K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$222K |
| 5 |
DC
Defender Capital
Charlotte,
North Carolina
|
+$202K |
Top Sellers
| 1 |
BlackRock
New York
|
-$5.05M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.49M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$915K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$577K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$350K |
LCTX Hedge Fund Activity: Q2 2020 in Review
94 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2020, worth a combined $48.5M — down 8.3% from $52.9M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of LCTX and 21 opened new positions — a net loss of 2 holders — while 20 trimmed existing stakes and 17 added.
The largest buyer was Jane Street, adding an estimated $710K. The largest seller was BlackRock, cutting an estimated $5.05M.
- 94 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2020, down from 97 in Q1 2020.
- Funds reported $48.5M of Lineage Cell Therapeutics stock for Q2 2020, down 8.3% quarter-over-quarter.
- 21 funds opened new Lineage Cell Therapeutics positions in Q2 2020 and 23 closed out, a net change of -2 holders.
- The largest Lineage Cell Therapeutics buyer in Q2 2020 was Jane Street, an estimated $710K added.
- The largest Lineage Cell Therapeutics seller in Q2 2020 was BlackRock, an estimated $5.05M sold.
Based on aggregated 13F filings for Q2 2020.